Strategic Initiative

Slingshot members are tracking this corporate initiative:

Leap Therapeutics (LPTX) and BeiGene (BGNE) Announce Exclusive Option and License Agreement for DKN-01 + $27 Million Equity Financing

Source Link:: https://investors.leaptx.com/news-releases/news-release-details/leap-therapeutics-and-beigene-announce-exclusive-option-and

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

BGNE

100%

LPTX

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Clinical Data - BeiGene granted option to develop and commercialize Leap's DKN-01 in the Asia Pacific Region, excluding Japan
- Initiation of combination studies of Leap's DKN-01 with BeiGene's anti-PD-1 antibody tislelizumab planned
In addition, Leap announced entering into an agreement for a $27 million equity financing with BeiGene and two institutional investors.

https://investors.le...

Slingshot Insights Explained

JOIN FOR FREE TODAY

Strategic Initiative Date

Announcement Date:

Jan 03, 2020

Projected Implementation:

Q1, 2020

Relevance Tracked Until:

Q2, 2020

Related Projects

Don’t see a project related to the strategic initiative you care about?

Related Keywords Dkn-01